Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Aculys Pharma Gets APAC Rights to Neurelis’ Epilepsy Nasal Spray
Aculys Pharma, a Japanese biotech specializing in neuroscience, said on January 24 that it has obtained exclusive Japan and Asia-Pacific rights for US peer Neurelis’ nasal spray containing diazepam for the treatment of epilepsy attacks. The two companies signed a…
To read the full story
Related Article
- Aculys Pharma Files Diazepam Nasal Spray in Japan
September 3, 2024
- Diazepam Nasal Spray Shows Efficacy in PIII Interim Analysis: Aculys
October 19, 2023
- Aculys Pharma Kicks Off Japan PIII of Diazepam Nasal Spray
November 11, 2022
- Aculys, KNOCK ON THE DOOR Form Comprehensive Epilepsy Alliance
July 5, 2022
BUSINESS
- Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
April 10, 2026
- Zenyaku, Chugai to End Rituxan Co-Promotion in September
April 10, 2026
- Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
April 10, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…